Wright, Exactech under investigation
This article was originally published in The Gray Sheet
Executive Summary
Wright Medical and Exactech are the latest orthopedic device makers to find themselves under investigation by the Department of Justice, having separately announced receipt of subpoenas during the week of Dec. 10. DoJ is requesting documents from 1998 through the present related to consulting and professional service agreements between the companies and orthopedic surgeons implanting their artificial hips and knees. The announcement follows DoJ's September agreements with the top five orthopedic implant makers (Stryker, Zimmer, Biomet, Johnson & Johnson/DePuy and Smith & Nephew), including a total of $311 million in fines, to settle kickback charges related to the hip and knee sales between 2002 and 2006 (1"The Gray Sheet" Oct. 1, 2007, p. 3)
You may also be interested in...
Wright expects $8 million settlement
Orthopedic device maker Wright Medical Group set aside $8 million in its 2010 first quarter to cover a "probable" settlement with the U.S. Department of Justice related to an investigation into allegedly improper consulting and professional service agreements with surgeons, the company stated during a May 4 earnings call for the quarter ended March 31. CEO Gary Henley cautions, however, that there is no assurance regarding "if or when" the matter will be finalized. The DoJ investigation came to light in December 2007 (1"The Gray Sheet" Dec. 17, 2007). Earlier in 2007, four major orthopedic firms including Zimmer, J&J/Depuy Orthopedics, Biomet and Smith & Nephew paid a total of $311 million in fines to settle kickback charges related to their hip and knee sales between 2002 and 2006, and a fifth, Stryker, entered a non-prosecution agreement with the government, but was not subject to criminal charges or a costly settlement (2"The Gray Sheet" Oct. 1, 2007)
Ortho Industry Reaches $311 Mil. Settlement With DoJ On Kickback Charges
Four major hip and knee implant manufacturers will pay the government a total of $311 million to settle anti-kickback claims resulting from a two-year Department of Justice and HHS investigation into the companies' financial relationships with surgeons, the New Jersey U.S. Attorney's office announced Sept. 27
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.